Michael Keyoung, MD, PhD is currently Managing Director and Head of North America at CBC Group (formerly known as C-Bridge Capital), a healthcare-dedicated private equity firm with over US$2 Billion AUM. Prior to joining CBC Group, Dr. Keyoung was President and CEO of Genexine Inc.(KOSDAQ:095700), over US$1 Billion market cap clinical stage biotech company developing innovative biologics in immuno-oncology, metabolic and rare diseases. Dr. Keyoung is Founding Managing Partner of Portola Capital Partners, a healthcare-dedicated investment and advisory firm investing in private and public biotech companies in the US. Previously he also served as President of Catalyst Biosciences (NASDAQ:CBIO), Hemophilia and Ophthalmology focused clinical stage company. He was also Managing Director and Head of Pan-Asia at US venture capital firm where he oversaw investments in private and public biotech and medtech companies. Throughout his career, he has advised leading healthcare companies such as Eli Lilly, Bausch & Lomb, UCB, Samsung Electronics/Samsung Biologics, Kalbe Pharma and Green Cross in global drug development, commercial strategies and partnerships or their regional expansion to Asia. Dr. Keyoung received both his Medical Doctorate and Ph.D. in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center as a Tri-Institutional Medical Scientist Training Program recipient at Cornell Weill, Memorial Sloan Kettering and Rockefeller University. He was a Howard Hughes Medical Institute fellow and received his clinical surgical training at the University of California, San Francisco.